Valeant to Rule Derm Market in $2.6B Medicis Acquisition
When J. Michael Pearson, CEO of Valeant Pharmaceuticals International Inc., reached out to Medicis Pharmaceuticals International Inc. to discuss terms for a potential merger, it was the third time the two companies had had such discussions in the last 18 months. In previous talks, the value of Medicis' broad-spectrum tetracycline antibiotic, Solodyn (minocycline), had been a sticking point.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter